CoChat
Sign Up
Cited by 62

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Research and development of drug delivery systems based on drug transporter and nano-formulation

Peng, Yi, Chen, Lu, Ye, Sheng, Kang, Yu, Liu, Junqing, Zeng, Su, Yu, Lushan·2020·Asian Journal of Pharmaceutical Sciences
DOI 10.1016/j.ajps.2020.02.004PMC PMC7193453
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajps.2020.02.004

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract Graphical abstract Some medicines enter or exit target cells through transporters. Nano-agents targeting transporters can enhance the targeted uptake of the drug while prevent the efflux of it.
Graphical abstract Graphical abstract Some medicines enter or exit target cells through transporters. Nano-agents targeting transporters can enhance the targeted uptake of the drug while prevent the efflux of it.CC BY-NC-ND · PubMed Central
Fig. 1 Drug Transporter family.
Fig. 1 Drug Transporter family.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 140

  1. Cocucci, 2017, Role of passive diffusion, transporters, and membrane trafficking-mediated processes in cellular drug transport, Clin Pharmacol Ther, 101, 121, 10.1002/cpt.545 · DOI
  2. Matsumoto, 2017, Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease?, Acta Neuropathol Com, 5, 71, 10.1186/s40478-017-0470-4 · DOI · Paper page
  3. Chavda, 2010, Biopharmaceutics classification system, Sys Rev Pharm, 1, 62, 10.4103/0975-8453.59514 · DOI
  4. Lammers, 2012, Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress, J Control Release, 161, 175, 10.1016/j.jconrel.2011.09.063 · DOI · Paper page
  5. Estudante, 2013, Intestinal drug transporters: an overview, Adv Drug Deliv Rev, 65, 1340, 10.1016/j.addr.2012.09.042 · DOI
  6. De Boer, 2003, The role of drug transporters at the blood-brain barrier, Annu Rev Pharmacol Toxicol, 43, 629, 10.1146/annurev.pharmtox.43.100901.140204 · DOI
  7. Halilbasic, 2013, Bile acid transporters and regulatory nuclear receptors in the liver and beyond, J Hepatol, 58, 155, 10.1016/j.jhep.2012.08.002 · DOI
  8. Motohashi, 2002, Gene expression levels and immunolocalization of organic ion transporters in the human kidney, J Am Soc Nephrol, 13, 866, 10.1681/ASN.V134866 · DOI
  9. Kalliokoski, 2009, Impact of OATP transporters on pharmacokinetics, Br J Pharmacol, 158, 693, 10.1111/j.1476-5381.2009.00430.x · DOI
  10. König, 2006, Pharmacogenomics of human OATP transporters, N-S Arch Pharmacol, 372, 432, 10.1007/s00210-006-0040-y · DOI
  11. Yang, 2016, siRNA capsulated brain-targeted nanoparticles specifically knock down OATP2B1 in mice: a mechanism for acute morphine tolerance suppression, Sci Rep, 6, 33338, 10.1038/srep33338 · DOI
  12. Zhou, 2008, Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development, Curr Med Chem, 15, 1981, 10.2174/092986708785132870 · DOI · Paper page
  13. Roth, 2012, OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies, Brit J Pharmacol, 165, 1260, 10.1111/j.1476-5381.2011.01724.x · DOI
  14. Rizwan, 2007, Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles, Pharm Res-dordrv, 24, 450, 10.1007/s11095-006-9181-4 · DOI
  15. Burckhardt, 2012, Drug transport by organic anion transporters (OATs), Pharmacol Therapeut, 136, 106, 10.1016/j.pharmthera.2012.07.010 · DOI
  16. Nieskens, 2016, A human renal proximal tubule cell line with stable organic anion transporter 1 and 3 expression predictive for antiviral-induced toxicity, AAPS J, 18, 465, 10.1208/s12248-016-9871-8 · DOI
  17. Müller, 2005, Drug specificity and intestinal membrane localization of human organic cation transporters (OCT), Biochem Pharmacol, 70, 1851, 10.1016/j.bcp.2005.09.011 · DOI
  18. Koepsell, 2007, Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications, Pharm Res-dordrv, 24, 1227, 10.1007/s11095-007-9254-z · DOI
  19. Koepsell, 2015, Role of organic cation transporters in drug–drug interaction, Expert Opin Drug Met, 11, 1, 10.1517/17425255.2015.1069274 · DOI
  20. Umehara, 2008, Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1–3 in vitro and implications for drug–drug interactions, Xenobiotica, 38, 1203, 10.1080/00498250802334409 · DOI
  21. Rubio-Aliaga, 2002, Mammalian peptide transporters as targets for drug delivery, Trends Pharmacol Sci, 23, 434, 10.1016/S0165-6147(02)02072-2 · DOI
  22. Vasiliou, 2009, Human ATP-binding cassette (ABC) transporter family, Hum Genomics, 3, 281, 10.1186/1479-7364-3-3-281 · DOI
  23. Demeule, 2002, Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood–brain barrier, Vasc Pharmacol, 38, 339, 10.1016/S1537-1891(02)00201-X · DOI
  24. Samanian, 2011, MDR1 gene polymorphisms: possible association with its expression and clinicopathology characteristics in colorectal cancer patients, Asian Pac J Cancer P, 12, 3141
  25. Cantore, 2016, Design and synthesis of new selective P-gp substrates and inhibitors, Curr Pharm Des, 22, 1, 10.2174/1381612822666160810114008 · DOI
  26. Cui, 2019, Flavonoids as P-gp inhibitors: a systematic review of SARs, Curr Med Chem, 26, 4799, 10.2174/0929867325666181001115225 · DOI
  27. Cheon, 2017, P-gp inhibition by XL019, a JAK2 inhibitor, increases apoptosis of vincristine-treated resistant kbv20c cells with increased p21 and pH2AX expression, Anticancer Res, 37, 6761
  28. Dash, 2017, Selection of P-Glycoprotein inhibitor and formulation of combinational nanoformulation containing selected agent curcumin and dox for reversal of resistance in K562 cells, Pharm Res, 34, 1741, 10.1007/s11095-017-2182-7 · DOI
  29. Sodani, 2012, Multidrug resistance associated proteins in multidrug resistance, Chin J Cancer, 31, 58, 10.5732/cjc.011.10329 · DOI
  30. Nies, 2001, Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma, Int J Cancer, 94, 492, 10.1002/ijc.1498 · DOI
  31. Leslie, 2005, Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense, Toxicol Appl Pharm, 204, 216, 10.1016/j.taap.2004.10.012 · DOI
  32. Scheffer, 2000, Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies, Cancer Res, 60, 5269
  33. Berthier, 2019, Multidrug resistance-associated protein 4 in pharmacology: overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics, Life Sci, 231, 10.1016/j.lfs.2019.06.015 · DOI
  34. Peterson, 2017, High-content screening of clinically tested anticancer drugs identifies novel inhibitors of human MRP1 (ABCC1), Pharmacol Res, 119, 313, 10.1016/j.phrs.2017.02.024 · DOI
  35. Nakanishi, 2012, Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression, Chin J Cancer, 31, 73, 10.5732/cjc.011.10320 · DOI
  36. Nickel, 2017, Expression and activity of breast cancer resistance protein (BCRP/ABCG2) in human distal lung epithelial cells in vitro, Pharm Res, 34, 2477, 10.1007/s11095-017-2172-9 · DOI
  37. Mao, 2015, Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport–an update, AAPS J, 17, 65, 10.1208/s12248-014-9668-6 · DOI
  38. Staud, 2005, Breast cancer resistance protein (BCRP/ABCG2), Int J Biochem Cell Biol, 37, 720, 10.1016/j.biocel.2004.11.004 · DOI
  39. Omote, 2006, The mate proteins as fundamental transporters of metabolic and xenobiotic organic cations, Trends Pharmacol Sci, 27, 587, 10.1016/j.tips.2006.09.001 · DOI
  40. Phan, 2003, Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor, Antimicrob Agents Chemother, 47, 2351, 10.1128/AAC.47.7.2351-2353.2003 · DOI
  41. Nakakariya, 2016, Appropriate risk criteria for oatp inhibition at the drug discovery stage based on the clinical relevancy between OATP inhibitors and drug-induced adverse effect, Drug Metab Pharmacokinet, 31, 333, 10.1016/j.dmpk.2016.05.003 · DOI
  42. Yu, 2017, Intestinal drug interactions mediated by OATPs: a systematic review of preclinical and clinical findings, J Pharm Sci, 106, 2312, 10.1016/j.xphs.2017.04.004 · DOI
  43. Wang, 2019, Organic anion transporter 3 (OAT3)-mediated transport of dicaffeoylquinic acids and prediction of potential drug-drug interaction, Eur J Pharm Sci, 133, 95, 10.1016/j.ejps.2019.03.022 · DOI
  44. Huo, 2019, Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs), Acta Pharm Sin B, 9, 986, 10.1016/j.apsb.2019.02.005 · DOI
  45. Hua, 2012, The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins, Cardiovasc Ther, 30, e234, 10.1111/j.1755-5922.2011.00290.x · DOI
  46. Liu, 2016, Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin, Sci Transl Med, 8, 348ra97, 10.1126/scitranslmed.aaf3124 · DOI
  47. König, 2013, Transporters and drug-drug interactions: important determinants of drug disposition and effects, Pharmacol Rev, 65, 944, 10.1124/pr.113.007518 · DOI
  48. Yu, 2017, Injectable drug-loaded nanocarriers for lung cancer treatments, Curr Pharm Des, 23, 481, 10.2174/1381612822666161027113654 · DOI
  49. Wang, 2016, Synthesis and characterization of poly(lactic acid-co-glycolic acid) complex microspheres as drug carriers, J Biomater Appl, 31, 544, 10.1177/0885328216657548 · DOI
  50. Andhariya, 2016, Recent advances in testing of microsphere drug delivery systems, Expert Opin Drug Deliv, 13, 593, 10.1517/17425247.2016.1134484 · DOI
  51. Zhang, 2013, Development and evaluation of a novel phytosome-loaded chitosan microsphere system for curcumin delivery, Int J Pharm, 448, 168, 10.1016/j.ijpharm.2013.03.021 · DOI
  52. Patil, 2008, Mucoadhesive microspheres: a promising tool in drug delivery, Curr Drug Deliv, 5, 312, 10.2174/156720108785914970 · DOI
  53. Lin, 2015, Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases, Hum Vaccin Immunother, 11, 650, 10.1080/21645515.2015.1009345 · DOI
  54. Farooq, 2014, Advancement in microsphere preparation using natural polymers and recent patents, Recent Pat Drug Deliv Formul, 8, 111, 10.2174/1872211308666140218110520 · DOI
  55. Young, 2016, Nanoparticle-siRNA: a potential cancer therapy?, Crit Rev Oncol Hematol, 98, 159, 10.1016/j.critrevonc.2015.10.015 · DOI
  56. Yuliana, 2015, PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting, Nanomedicine, 10, 1735, 10.2217/nnm.15.29 · DOI
  57. Zhang, 2017, Ascorbyl palmitate/d-α-tocopheryl polyethylene glycol 1000 succinate monoester mixed micelles for prolonged circulation and targeted delivery of compound K for antilung cancer therapy in vitro and in vivo, Int J Nanomedicine, 12, 605, 10.2147/IJN.S119226 · DOI
  58. Rode, 2018, Carbon nanotubes: classification, method of preparation and pharmaceutical application, Curr Drug Deliv, 15, 620, 10.2174/1567201815666171221124711 · DOI
  59. Alhans, 2018, Comparative analysis of single-walled and multi-walled carbon nanotubes for electrochemical sensing of glucose on gold printed circuit boards, Mater Sci Eng C Mater Biol Appl, 90, 273, 10.1016/j.msec.2018.04.072 · DOI
  60. Ren, 2012, The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2, Biomaterials, 33, 3324, 10.1016/j.biomaterials.2012.01.025 · DOI
  61. Varshosaz, 2015, Hollow inorganic nanoparticles as efficient carriers for siRNA delivery: a comprehensive review, Curr Pharm Des, 21, 4310, 10.2174/1381612821666150901103937 · DOI
  62. Rao, 2016, Synthetic nanoparticles camouflaged with biomimetic erythrocyte membranes for reduced reticuloendothelial system uptake, Nanotechnology, 27, 10.1088/0957-4484/27/8/085106 · DOI
  63. Gómez-Vallejo, 2018, PEG-copolymer-coated iron oxide nanoparticles that avoid the reticuloendothelial system and act as kidney MRI contrast agents, Nanoscale, 10, 14153, 10.1039/C8NR03084G · DOI
  64. Talkar, 2018, Transmucosal nanoparticles: toxicological overview, Adv Exp Med Biol, 1048, 37, 10.1007/978-3-319-72041-8_3 · DOI
  65. Agrawal, 2017, Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease, J Control Release, 260, 61, 10.1016/j.jconrel.2017.05.019 · DOI · Paper page
  66. Iqbal, 2017, Targeted drug delivery systems and their therapeutic applications in cancer and immune pathological conditions, Infect Disord Drug Targets, 17, 149, 10.2174/1871526517666170606102623 · DOI
  67. Elhissi, 2017, Liposomes for pulmonary drug delivery: the role of formulation and inhalation device design, Curr Pharm Des, 23, 362, 10.2174/1381612823666161116114732 · DOI
  68. Li, 2019, Composition design and medical application of liposomes, Eur J Med Chem, 164, 640, 10.1016/j.ejmech.2019.01.007 · DOI
  69. Fan, 2017, Study of the pH-sensitive mechanism of tumor-targeting liposomes, Colloids Surf B Biointerfaces, 151, 19, 10.1016/j.colsurfb.2016.11.042 · DOI
  70. Halevas, 2019, Magnetic cationic liposomal nanocarriers for the efficient drug delivery of a curcumin-based vanadium complex with anticancer potential, J Inorg Biochem, 199, 110778, 10.1016/j.jinorgbio.2019.110778 · DOI
  71. Noble, 2004, Development of ligand-targeted liposomes for cancer therapy, Expert Opin Ther Targets, 8, 335, 10.1517/14728222.8.4.335 · DOI
  72. Cao, 2017, Magnetic-Immuno-Loop-Mediated isothermal amplification based on dna encapsulating liposome for the ultrasensitive detection of P-glycoprotein, Sci Rep, 7, 9312, 10.1038/s41598-017-10133-3 · DOI
  73. Huang, 2019, Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs, J Control Release, 310, 47, 10.1016/j.jconrel.2019.08.006 · DOI
  74. Pradhan, 2010, Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy, J Control Release, 142, 108, 10.1016/j.jconrel.2009.10.002 · DOI
  75. Palmerston Mendes, 2017, Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy, Molecules, 22, 1401, 10.3390/molecules22091401 · DOI · Paper page
  76. Liu, 2018, Loading IR820 using multifunctional dendrimers with enhanced stability and specificity, Pharmaceutics, 10, 77, 10.3390/pharmaceutics10030077 · DOI
  77. Eichman, 2000, The use of pamam dendrimers in the efficient transfer of genetic material into cells, Pharm Sci Technolo Today, 3, 232, 10.1016/S1461-5347(00)00273-X · DOI
  78. Li, 2016, Selenium-Platinum coordination dendrimers with controlled anti-cancer activity, ACS Appl Mater Interfaces, 8, 3609, 10.1021/acsami.5b07877 · DOI
  79. Tambe, 2017, Surface engineered dendrimers in sirna delivery and gene silencing, Curr Pharm Des, 23, 2952, 10.2174/1381612823666170314104619 · DOI
  80. Somani, 2018, PEGylation of polypropylenimine dendrimers: effects on cytotoxicity, DNA condensation, gene delivery and expression in cancer cells, Sci Rep, 8, 9410, 10.1038/s41598-018-27400-6 · DOI
  81. Dobrovolskaia, 2017, Dendrimers effects on the immune system: insights into toxicity and therapeutic utility, Curr Pharm Des, 23, 3134, 10.2174/1381612823666170309151958 · DOI
  82. Yousefpour Marzbali, 2017, Polymeric micelles as mighty nanocarriers for cancer gene therapy: a review, Cancer Chemother Pharmacol, 79, 637, 10.1007/s00280-017-3273-1 · DOI · Paper page
  83. Rey-Rico, 2018, PEO-PPO-PEO tri-block copolymers for gene delivery applications in human regenerative medicine-an overview, Int J Mol Sci, 19, 775, 10.3390/ijms19030775 · DOI
  84. Oerlemans, 2010, Polymeric micelles in anticancer therapy: targeting, imaging and triggered release, Pharm Res, 27, 2569, 10.1007/s11095-010-0233-4 · DOI
  85. Rashed, 2016, Contribution of both olfactory and systemic pathways for brain targeting of nimodipine-loaded lipo-pluronics micelles: in vitro characterization and in vivo biodistribution study after intranasal and intravenous delivery, Drug Deliv, 24, 181, 10.1080/10717544.2016.1236848 · DOI
  86. Sonali, 2016, Transferrin receptor-targeted vitamin E TPGS micelles for brain cancer therapy: preparation, characterization and brain distribution in rats, Drug Deliv, 23, 1788, 10.3109/10717544.2015.1094681 · DOI
  87. Zhang, 2012, Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation, J Control Release, 159, 429, 10.1016/j.jconrel.2012.01.031 · DOI
  88. Yokoyama, 2014, Polymeric micelles as drug carriers: their lights and shadows, J Drug Target, 22, 576, 10.3109/1061186X.2014.934688 · DOI
  89. Aboulfotouh, 2018, Self-emulsifying drug-delivery systems modulate P-glycoprotein activity: role of excipients and formulation aspects, Nanomedicine (Lond), 0354
  90. Bhandari, 2017, Antimalarial solid self-emulsifying system for oral use: in vitro investigation, Ther Deliv, 8, 201, 10.4155/tde-2016-0092 · DOI
  91. Zhongyao, 2018, Nanocrystals technology for pharmaceutical science, Curr Pharm Des, 24, 2497, 10.2174/1381612824666180518082420 · DOI
  92. Pardhi, 2018, Nanocrystals: an overview of fabrication, characterization and therapeutic applications in drug delivery, Curr Pharm Des, 24, 5129, 10.2174/1381612825666190215121148 · DOI
  93. Staples, 2010, Microchips and controlled-release drug reservoirs, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2, 400, 10.1002/wnan.93 · DOI
  94. Lee, 2015, An implantable drug-delivery system on a chip, Curr Top Med Chem, 15, 1516, 10.2174/1568026615666150414121427 · DOI
  95. Sutradhar, 2016, Implantable microchip: the futuristic controlled drug delivery system, Drug Deliv, 23, 1, 10.3109/10717544.2014.903579 · DOI
  96. Lee, 2014, Implantable micro-chip for controlled delivery of diclofenac sodium, J Control Release, 196, 52, 10.1016/j.jconrel.2014.09.019 · DOI
  97. Eltorai, 2016, Microchips in medicine: current and future applications, Biomed Res Int, 2016, 10.1155/2016/1743472 · DOI
  98. Mokhtar, 2017, Design of PEG-grafted-PLA nanoparticles as oral permeability enhancer for P-gp substrate drug model famotidine, J Microencapsul, 34, 91, 10.1080/02652048.2017.1290155 · DOI
  99. Essa, 2010, Effect of polyethylene glycol (PEG) chain organization on the physicochemical properties of poly(D, L-lactide) (PLA) based nanoparticles, Eur J Pharm Biopharm, 75, 96, 10.1016/j.ejpb.2010.03.002 · DOI
  100. Yang, 2017, A large-inner-diameter multi-walled carbon nanotube-based dual-drug delivery system with pH-sensitive release properties, J Mater Sci Mater Med, 28, 110, 10.1007/s10856-017-5920-9 · DOI
  101. Thipparaboina, 2015, Micellar carriers for the delivery of multiple therapeutic agents, Colloids Surf B Biointerfaces, 135, 291, 10.1016/j.colsurfb.2015.07.046 · DOI
  102. Choi, 2014, ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development, Curr Pharm Des, 20, 793, 10.2174/138161282005140214165212 · DOI
  103. Abdallah, 2015, P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review, J Adv Res, 6, 45, 10.1016/j.jare.2014.11.008 · DOI
  104. Joshi, 2017, Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer, Eur J Med Chem, 138, 273, 10.1016/j.ejmech.2017.06.047 · DOI
  105. Huarte, 2016, Oral delivery of camptothecin using cyclodextrin/poly(anhydride) nanoparticles, Int J Pharm, 506, 116, 10.1016/j.ijpharm.2016.04.045 · DOI
  106. Qi, 2011, Antitumor activity of extracts and compounds from the skin of the toad BUFO bufo gargarizans cantor, Int Immunopharmacol, 11, 342, 10.1016/j.intimp.2010.12.007 · DOI
  107. Ren, 2019, Near-infrared fluorescent carbon dots encapsulated liposomes as multifunctional nano-carrier and tracer of the anticancer agent cinobufagin in vivo and in vitro, Colloids Surf B Biointerfaces, 174, 384, 10.1016/j.colsurfb.2018.11.041 · DOI
  108. Battistella, 2017, Reversion of P-gp-Mediated drug resistance in ovarian carcinoma cells with PHPMA-Zosuquidar conjugates, Biomacromolecules, 18, 1855, 10.1021/acs.biomac.7b00291 · DOI
  109. Sivak, 2017, Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate, Biomaterials, 115, 65, 10.1016/j.biomaterials.2016.11.013 · DOI
  110. Shafiei-Irannejad, 2018, Reversion of multidrug resistance by co-encapsulation of doxorubicin and metformin in poly(lactide-co-glycolide)-D-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles, Pharm Res, 35, 119, 10.1007/s11095-018-2404-7 · DOI
  111. Fatma, 2016, Novel flavonoid-based biodegradable nanoparticles for effective oral delivery of etoposide by P-glycoprotein modulation: an in vitro, ex vivo and in vivo investigations, Drug Deliv, 23, 500, 10.3109/10717544.2014.923956 · DOI
  112. Bar-Zeev, 2018, β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer, Eur J Pharm Biopharm, 133, 240, 10.1016/j.ejpb.2018.10.018 · DOI
  113. Hu, 2016, LHD-Modified mechanism-based liposome coencapsulation of mitoxantrone and prednisolone using novel lipid bilayer fusion for tissue-specific colocalization and synergistic antitumor effects, ACS Appl Mater Interfaces, 8, 6586, 10.1021/acsami.5b10598 · DOI
  114. Buddolla, 2018, Recent insights into the development of nucleic acid-based nanoparticles for tumor-targeted drug delivery, Colloids Surf B Biointerfaces, 172, 315, 10.1016/j.colsurfb.2018.08.057 · DOI
  115. Zhao, 2018, Polyester-based nanoparticles for nucleic acid delivery, Mater Sci Eng C Mater Biol Appl, 92, 983, 10.1016/j.msec.2018.07.027 · DOI
  116. Tong, 2018, Delivery of siRNA in vitro and in vivo using PEI-capped porous silicon nanoparticles to silence MRP1 and inhibit proliferation in glioblastoma, J Nanobiotechnology, 16, 38, 10.1186/s12951-018-0365-y · DOI
  117. Xu, 2015, Down-regulation of MRP1 expression in C6/VP16 cells by chitosan-mrp1-sirna nanoparticles, Cell Biochem Biophys, 72, 227, 10.1007/s12013-014-0442-2 · DOI
  118. Zhang, 2018, Overcoming multidrug resistance by codelivery of MDR1-Targeting siRNA and doxorubicin using epha10-mediated pH-Sensitive lipoplexes: in vitro and in vivo evaluation, ACS Appl Mater Interfaces, 10, 21590, 10.1021/acsami.8b01806 · DOI
  119. Risnayanti, 2018, PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer, Sci Rep, 8, 7498, 10.1038/s41598-018-25930-7 · DOI
  120. Pan, 2019, Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance, Eur J Pharm Biopharm, 136, 18, 10.1016/j.ejpb.2019.01.006 · DOI
  121. Wu, 2018, Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery, Biomater Sci, 6, 1457, 10.1039/C8BM00226F · DOI
  122. Zhang, 2019, Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition, J Cell Biochem, 120, 13037, 10.1002/jcb.28574 · DOI
  123. Ahmad, 2017, Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer, Artif Cells Nanomed Biotechnol, 46, 1
  124. Chen, 2018, Rational design of redox-responsive and P-gp-Inhibitory lipid nanoparticles with high entrapment of paclitaxel for tumor therapy, Adv Healthc Mater, 7, e1800485, 10.1002/adhm.201800485 · DOI
  125. Madgulkar, 2017, Improvement of oral bioavailability of lopinavir without co-administration of ritonavir using microspheres of thiolated xyloglucan, AAPS PharmSciTech, 19, 1
  126. Soundararajan, 2016, Direct in vivo evidence on the mechanism by which nanoparticles facilitate the absorption of a water insoluble, P-gp substrate, Int J Pharmaceut, 514, 121, 10.1016/j.ijpharm.2016.08.013 · DOI
  127. Dong, 2009, Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP, Cancer Res, 69, 3918, 10.1158/0008-5472.CAN-08-2747 · DOI
  128. Tummala, 2016, Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors, Drug Deliv, 23, 1773, 10.3109/10717544.2015.1084400 · DOI · Paper page
  129. Tummala, 2016, Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles, Drug Deliv, 23, 3505, 10.1080/10717544.2016.1199606 · DOI
  130. Ahmed, 2018, Evaluation of antiproliferative activity, safety and biodistribution of oxaliplatin and 5-fluorouracil loaded lactoferrin nanoparticles for the management of colon adenocarcinoma: an in vitro and an in vivo study, Pharm Res, 35, 178, 10.1007/s11095-018-2457-7 · DOI
  131. Chaves, 2017, Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain, Curr Neuropharmacol, 15, 1156, 10.2174/1570159X15666170504095823 · DOI
  132. Kou, 2018, Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5), Expert Opin Ther Targets, 22, 715, 10.1080/14728222.2018.1502273 · DOI
  133. Tsuji, 1998, P-Glycoprotein-Mediated efflux transport of anticancer drugs at the blood-brain barrier, Ther Drug Monit, 20, 588, 10.1097/00007691-199810000-00024 · DOI
  134. Fabel, 2001, Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin, Cancer, 92, 1936, 10.1002/1097-0142(20011001)92:7<1936::AID-CNCR1712>3.0.CO;2-H · DOI
  135. De Vries, 2012, Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP, Invest New Drug, 30, 443, 10.1007/s10637-010-9569-1 · DOI
  136. Lakkadwala, 2019, Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model, Colloid Surface B, 173, 27, 10.1016/j.colsurfb.2018.09.047 · DOI
  137. Yin, 2015, Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease, Acta Biomater, 25, 172, 10.1016/j.actbio.2015.06.035 · DOI
  138. Fan, 2018, Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer's disease, Drug Deliv, 25, 1091, 10.1080/10717544.2018.1461955 · DOI
  139. Xia, 2014, l-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review, J Thorac Dis, 6, 1513
  140. Douer, 2016, Efficacy and safety of vincristine sulfate liposome injection in the treatment of adult acute lymphocytic leukemia, Oncologist, 21, 840, 10.1634/theoncologist.2015-0391 · DOI

Cited by

Sorted by citations

Metadata

Authors
Peng, Y., Chen, L., Ye, S., Kang, Y., Liu, J., Zeng, S., & Yu, L.
Venue
Asian Journal of Pharmaceutical Sciences
Publisher
Elsevier BV
Published
2020-03
Volume
15
Issue
2
Pages
220-236
ISSN
1818-0876
DOI
10.1016/j.ajps.2020.02.004
PMC
PMC7193453
Cited by
62
References
2
Language
en
Licence
Funders
National Natural Science Foundation of China

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review